Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2017 | Clinical evidence supporting rituximab

Won-Seog Kim • 13 Jun 2017
ICML 2017
Chronic Lymphocytic Leukemia Rituximab

Won Seog Kim, MD, PhD from Sungkyunkwan University, Seoul, South Korea discusses his presentation on the biosimilar rituximab, given during the International Conference on Malignant Lymphoma (ICML) 2017, Lugano, Switzerland. Prof. Kim describes the process of biosimilar production and how this differs from the manufacturing of originator biologics. Providing an overview of the data he presented, Prof. Kim speaks about the efficacy of rituximab in the treatment of chronic lymphocytic leukemia and the supporting clinical evidence. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.

More from Won-Seog Kim

1:11
DISTINKT trial analysis: efficacy and safety of IMC-001 for R/R ENKTL
Won-Seog Kim • 16 Jun 2023
1:35
REDIRECT results: AFM13 in patients with CD30+ R/R PTCL
Won-Seog Kim • 16 Jun 2023
1:07
Golidocitinib in R/R PTCL: analysis of the JACKPOT8 trial
Won-Seog Kim • 16 Jun 2023
1:09
Interim analysis of anbal-cel for R/R DLBCL
Won-Seog Kim • 16 Jun 2023

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals